Aptose Biosciences is a clinical-stage oncology company pioneering targeted therapies, often referred to as precision medicines, that offer new and personalized treatment strategies for patients with life-threatening hematologic malignancies (cancers of the blood, bone marrow and lymphoid tissues).  Aptose is a publicly traded company on the NASDAQ (ticker symbol: APTO) and TSX (ticker symbol: APS) exchanges, and is applying fresh scientific insights to the development of three highly differentiated targeted agents.  Aptose’s leadership team and advisory board are comprised of accomplished industry, financial and clinical research professionals and key opinion leaders (KOLs) who are dedicated to building a comprehensive anticancer drug pipeline and clinical development programs.